Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 27, 2025; 17(10): 110402
Published online Oct 27, 2025. doi: 10.4254/wjh.v17.i10.110402
Published online Oct 27, 2025. doi: 10.4254/wjh.v17.i10.110402
Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice
Shu Niu, Department of Endocrinology, Shijiazhuang People's Hospital, Shijiazhuang 050011, Hebei Province, China
Shu Niu, Shu-Chun Chen, Department of Endocrinology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China
Chen-Xi Wang, Department of Endocrine, Hebei Medical University, Shijiazhuang 050011, Hebei Province, China
Lin Yue, Department of Endocrine, The Third Hospital of Shijiazhuang, Shijiazhuang 050011, Hebei Province, China
Shu-Qi Wang, Department of Internal Medical, Hebei General Hospital, Shijiazhuang 050011, Hebei Province, China
Author contributions: Niu S and Chen SC conceived and designed the experiments, performed the experiments and wrote the paper; Niu S, Wang CX, Lin Y, and Wang SQ analyzed and interpreted the data; all authors contributed to the article and approved the submitted version.
Supported by The Scientific Research Programme on Traditional Chinese Medicine in Hebei Province, No. 2024127.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of Hebei General Hospital, No. 202332.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at chenshuc2014@163.com.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Chun Chen, PhD, Professor, Department of Endocrinology, Hebei General Hospital, No. 348 Heping West Road, Shijiazhuang 050051, Hebei Province, China.
Received: June 5, 2025
Revised: July 23, 2025
Accepted: September 1, 2025
Published online: October 27, 2025
Processing time: 143 Days and 22.9 Hours
Revised: July 23, 2025
Accepted: September 1, 2025
Published online: October 27, 2025
Processing time: 143 Days and 22.9 Hours
Core Tip
Core Tip: The present study demonstrated that semaglutide and empagliflozin reduced body weight, ameliorated disorders of glucose and lipid metabolism, lowered levels of inflammation and oxidative stress, and attenuated metabolic dysfunction-associated steatotic liver disease in obese mice. The following section outlines possible mechanisms for reducing the levels of various lysophosphatidylcholines.